Search for Studies
Search Results
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Conditions:
Staphylococcus Aureus BacteremiaLocation:
- Peter Lougheed Centre, Calgary, Alberta, Canada
- University of Alberta Hospital, Edmonton, Alberta, Canada
- St. Boniface Hospital, Winnipeg, Manitoba, Canada
- Eastern Regional Health Authority - St. Clare's Mercy Hospital, Saint John's, Newfoundland and Labrador, Canada
- Hamilton Health Sciences - Juravinski Hospital, Hamilton, Ontario, Canada
- The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada
- Unity Health - St Michael's Hospital, Toronto, Ontario, Canada
- University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada
- McGill University Health Centre - Montreal Children's Hospital, Montréal, Quebec, Canada
- University of Sherbrooke Health Centre - Hotel Dieu, Sherbrooke, Quebec, Canada
- South Health Campus, Calgary, Alberta, Canada
- Vancouver General Hospital, Vancouver, British Columbia, Canada
- Eastern Health - Health Sciences Centre (Memorial University), Saint John's, Newfoundland and Labrador, Canada
- Hamilton Health Sciences - Hamilton General Hospital, Hamilton, Ontario, Canada
- Niagara Health - Niagara Falls Site, Niagara Falls, Ontario, Canada
- Niagara Health - St. Catharines Site, St. Catharines, Ontario, Canada
- Unity Health Toronto - St Joseph's Health Centre, Toronto, Ontario, Canada
- McGill University Health Centre - Montral General Hospital, Montréal, Quebec, Canada
- University of Sherbrooke Health Centre - Hospital Fleurimont, Sherbrooke, Quebec, Canada
- Foothills Medical Center, Calgary, Alberta, Canada
- Richmond Hospital, Richmond, British Columbia, Canada
- Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
- Toronto East Health Network - Michael Garron Hospital, East York, Ontario, Canada
- Kingston Health Sciences Centre - Kingston General Hospital, Kingston, Ontario, Canada
- The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- CISSS - Hôpital Cité-de-la-Santé Hospital, Laval, Quebec, Canada
- McGill University Health Centre - Royal Victoria Hospital, Montréal, Quebec, Canada
- Rockyview Hospital, Calgary, Alberta, Canada
- Fraser Health Authority - Surrey Memorial Hospital, Surrey, British Columbia, Canada
- Grace Hospital, Winnipeg, Manitoba, Canada
- University Health Network - Toronto General Hospital, East York, Ontario, Canada
- London Health Sciences Centre - University Hospital, LHSC, London, Ontario, Canada
- Sault Area Hospital, Sault-Sainte-Marie, Ontario, Canada
- Sinai Heath System - Mount Sinai Hospital, Toronto, Ontario, Canada
- Jewish General Hospital, Montréal, Quebec, Canada
- Hôpital Régional de Saint Jérôme, Saint-Jérôme, Quebec, Canada
Sex:
ALLAges:
AnyParkinson's disease (PD) is a lifelong and progressive disease and is the second most common progressive neurodegenerative disease worldwide. This study will examine whether there are significant differences in motor (e.g., balance and gait) and non-motor (e.g., cognition, mood, smell \& sleep ) symptoms and quality of life between the Real (active) at-home photobiomodulation (light therapy) combined with exercise group and the Placebo (sham) at-home photobiomodulation (light therapy) combined with exercise group. Each group (Real \& Placebo) will include 30 participants; with moderate PD, ages 55-80. Three outcome measurement sessions will be conducted; at the study entry and the end of Weeks 1 \& 4 after the last light therapy treatment. Exercise must have been part of the participant's routine before entering the study and will continue during and after the light therapy treatments have been completed.
Conditions:
Disease | Parkinson'sLocation:
- Gaitway Neurophysio and Parkinson's Wellness Innovation Centre, Hamilton, Ontario, Canada
Sex:
ALLAges:
55 - 80Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.
Conditions:
Type 1 Diabetes | Adolescent | Child | Cardiovascular ComplicationsLocation:
- Endocrine and Diabetes Unit, BC Children's Hospital, Vancouver, British Columbia, Canada
Sex:
ALLAges:
8 - 17This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death
Conditions:
Lung TransplantLocation:
- University Health Network/ Toronto General Hospital (Site #: 71121), Toronto, Ontario, Canada
Sex:
ALLAges:
12 - 75There is a need to identify strategies that improve the conduct of clinical trials involving family members of intensive care unit (ICU) patients. The purpose of the present study is to evaluate recruitment and retention strategies for clinical trials involving family members of ICU patients. 4 strategies (2 recruitment and 2 retention) will be tested. Investigators will integrate the strategies into three existing studies that involve family members of ICU patients. Participants will be randomized using a 2x2 factorial design. The co-primary outcomes are recruitment percentage (participants enrolled/participants approached) and retention percentage (participants completing follow-up/participants enrolled).
Conditions:
Recruitment | Retention | Family Members | Compensation Incentives | Study Enrollment | Clinical...Location:
- Jewish General Hospital, Montreal, Quebec, Canada
Sex:
ALLAges:
Over 18This is an observational study of the occurrence of cardiac toxicity in patients with breast cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline. Patients will be identified at the oncology clinic and will be included in the study if all eligible criteria are met. The study will involve retrospective and prospective evaluations. Safety will be assessed through reporting of serious adverse events (SAEs) related to study procedures.
Conditions:
Lymphoma | Breast Cancer | LeukemiaLocation:
- CISSSS de Lanaudière_Hôpital Pierre LeGardeur (referring site), Terrebonne, Quebec (QC), Canada
- CIUSSS du Centre-Ouest de l'Île de Montréal - Jewish General Hospital, Montréal, Quebec, Canada
- CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada
- Centre Hospitalier de l'université de Montréal (CHUM), Montreal, Quebec, Canada
- Montreal Heart Institute, Montréal, Quebec, Canada
- CIUSSS Ouest de l'ile de Montreal - St-Mary's Hospital, Montréal, Quebec, Canada
Sex:
ALLAges:
Over 18The primary purpose of this study is to characterize cardiovascular autonomic function to emotional stimuli (blood-injection-injury phobia \[needle phobia\]) during an orthostatic (upright) challenge in individuals with and without known needle phobia. It is well established that emotional stress can produce hypotensive (low blood pressure) reactions. Interestingly, these hypotensive reactions to venipuncture (even with minimal blood drawn), insulin injections, finger sticks for blood sugar monitoring, dental care, and vaccinations can affect up to a quarter of adults and appear to be uniquely associated with blood-injection-injury phobia rather than other phobias. These hypotensive reactions can ultimately lead to a vasovagal syncope (fainting) response, and lead to increased avoidance of medical and dental procedures as a result of this phobia. Ultimately, this has severe implications on public health and places additional strain on the Canadian healthcare system. Currently, there is limited understanding surrounding the initiation of this response. Additionally, a comprehensive profile of cardiovascular autonomic function during exposure to provoking stimuli during orthostatic stress has not been captured in the literature. We will test individuals with and without blood-injection-injury phobia using our standard approach while exposing them to emotional stimuli.
Conditions:
Syncope, Vasovagal | Blood, Injection, Injury Type PhobiaLocation:
- Simon Fraser University, Burnaby, British Columbia, Canada
Sex:
ALLAges:
18 - 50Prospective cohort study of patients receiving standard-care radiotherapy is paramount to a better understanding of radiation effects and longterm outcomes. The primary objective is to determine the feasibility of establishing infrastructure to systematically collect clinical data, patient-reported outcomes, and imaging data from daily radiotherapy practice. Secondary objectives are to provide a control cohort for comparative effectiveness research of investigational interventions through a cmRCT design; compare imaging features with clinical outcomes; understand dose-effect relationships; quantify imaging quality metrics.
Conditions:
Cancer | Radiotherapy Side EffectLocation:
- London Health Regional Cancer Centre, London, Ontario, Canada
- CHUQ, Québec, Quebec, Canada
- Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Centre de santé et de services sociaux de Laval, Laval, Quebec, Canada
Sex:
ALLAges:
Over 18Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are successfully treated. Currently, it is hard to predict when a depressive episode will recur. Being able to forecast this would help healthcare providers monitor patients and prevent relapse. The purpose of this study is to monitor features such as clinical symptoms, physical activity, sleep patterns, cognitive functioning and brain activity to help us understand how relapse happens and the mechanisms that cause it. From these different types of data, investigators will build a model that tells us who is more likely to experience a relapse and when the relapse is likely to occur. This study will be a significant step forward in understanding and managing MDD. Investigator will create a practical tool that will allow healthcare providers to monitor patients more effectively. By identifying early signs of relapse, investigators may be able to intervene promptly to prevent depressive episodes. Finally, our research will help understand the factors that underlie relapse in MDD, which will encourage the development of novel treatment approaches.
Conditions:
Major Depressive Disorder (MDD)Location:
- Nova Scotia Health, Halifax, Nova Scotia, Canada
Sex:
ALLAges:
18 - 70The overall goal of this research program is to determine quantitative predictors of quantitative long-term neurological functioning following different cardiac surgery procedures. The investigators aim to generate a timeline of neurological function that includes pre-existing performance, post-operative delirium, and neurological outcome. Furthermore, the investigators will test the hypothesis that intraoperative regional cerebral oxygenation (rSO2) desaturations, as measured by near-infrared spectroscopy (NIRS) are associated with poor neurological functioning following cardiac surgery, as measured by a robotic device called the KINARM.
Conditions:
Coronary Artery Disease | Cognitive Impairment | DeliriumLocation:
- Kingston General Hospital, Kingston, Ontario, Canada